HEALTHCARE TRUST OF AMERICA, INC. ANNOUNCES THIRD QUARTER 2022 PRO RATA DIVIDEND

Rhea-AI Summary

Healthcare Trust of America (NYSE: HTA) has announced a pro-rata quarterly dividend of $0.029 per share for its Class A Common Stock, to be paid on July 19, 2022, to shareholders on record as of July 14, 2022. This dividend represents a decrease from the previous quarterly dividend of $0.325 per share, reflecting a proration due to an upcoming merger with Healthcare Realty Trust Incorporated, expected to close on July 20, 2022.

Additionally, holders of HTA's operating partnership units will also receive a corresponding distribution.

Positive

• Continued dividend payments maintain investor confidence.
• Merger with Healthcare Realty Trust could enhance market position.

Negative

• Dividend payout significantly reduced from $0.325 to $0.029.
• Merger risks include potential delays and integration challenges.

SCOTTSDALE, Ariz., July 1, 2022 /PRNewswire/ -- Healthcare Trust of America, Inc. (NYSE: HTA) ("HTA"), the largest dedicated owner and operator of medical office buildings in the United States, announced today that its Board of Directors has approved a pro-rata quarterly dividend of $0.029 per share of Class A Common Stock. The dividend will be paid on July 19, 2022 to stockholders of record on July 14, 2022, and represents a proration of our previous quarterly dividend of $0.325 per share for the period beginning on our previous quarterly dividend record date and ending immediately prior to the expected closing date of the previously announced merger with Healthcare Realty Trust Incorporated ("HR").  Subject to a favorable shareholder vote, the merger is expected to close on July 20, 2022.

Additionally, the eligible holders of HTA's operating partnership units ("OP Units") will received a pro-rated quarterly OP Unit distribution, which is on par with HTA's Class A Common Stock dividend described above.

About Healthcare Trust of America, Inc.

Healthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of medical office buildings in the United States, with assets comprising approximately 26.0 million square feet of gross leasable area, and with $7.8 billion invested primarily in medical office buildings, as of March 31, 2022.  HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations.  Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions, which generally translates to superior demographics, highly-educated graduates, intellectual talent and job growth.  The strategic markets HTA invests in support a strong, long-term demand for quality medical office space.  HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market.  We believe this drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation.  Headquartered in Scottsdale, Arizona, HTA has developed a national brand with dedicated relationships at the local level.

Founded in 2006 and listed on the New York Stock Exchange in 2012, HTA has produced attractive returns for its stockholders that have outperformed the US REIT index, since inception.  More information about HTA can be found on the Company's Website (www.htareit.com), Facebook, LinkedIn and Twitter.

Forward-Looking Language

This press release contains certain forward-looking statements with respect to HTA. Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, plans or predictions of the future, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements. These risks, uncertainties and contingencies include, without limitation, the following: HTA's ability to consummate the Merger with HR on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary stockholder approvals and satisfaction of other closing conditions to consummate the Merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive merger agreement relating to the Merger; risks related to diverting the attention of HTA and HR management from ongoing business operations; failure to realize the expected benefits of the Merger; significant transaction costs and/or unknown or inestimable liabilities; risks associated with stockholder litigation in connection with the Merger, including resulting expense or delay; the risk that HTA's business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the ability to obtain the expected financing to consummate the Merger; risks related to future opportunities and plans for HTA, including the uncertainty of expected future financial performance and results of the combined company following completion of the Merger; effects relating to the announcement of the proposed transaction or any further announcements or the consummation of the Merger on the market price of HTA's or HR's common stock; the possibility that, if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial analysts or investors, the market price of HTA's common stock could decline; general adverse economic and local real estate conditions; changes in economic conditions generally and the real estate market specifically; legislative and regulatory changes, including changes to laws governing the taxation of REITs and changes to laws governing the healthcare industry; the availability of capital; changes in interest rates; competition in the real estate industry; the supply and demand for operating properties in HTA's proposed market areas; changes in accounting principles generally accepted in the US; policies and guidelines applicable to REITs; the availability of properties to acquire; the availability of financing; pandemics and other health concerns, and the measures intended to prevent their spread, including the currently ongoing COVID-19 pandemic; and the potential material adverse effect these matters may have on HTA's business, results of operations, cash flows and financial condition. Additional information concerning HTA and its business, including additional factors that could materially and adversely affect HTA's financial results, include, without limitation, the risks described under Part I, Item 1A – Risk Factors, in HTA's 2021 Annual Report on Form 10-K and in HTA's other filings with the SEC.

Financial Contact:
Robert A. Milligan
Chief Financial Officer
480.998.3478

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-trust-of-america-inc-announces-third-quarter-2022-pro-rata-dividend-301579856.html

SOURCE Healthcare Trust of America, Inc.

FAQ

What is the latest dividend amount declared by Healthcare Trust of America (HTA)?

HTA has declared a pro-rata quarterly dividend of $0.029 per share.

When will the next dividend payment for HTA be made?

The dividend will be paid on July 19, 2022.

What is the record date for the upcoming dividend payment for HTA?

The record date for the dividend is July 14, 2022.

How does the current dividend compare to previous payments?

The current dividend of $0.029 is a significant decrease from the previous payment of $0.325 per share.

What are the implications of the merger with Healthcare Realty Trust for HTA shareholders?

The merger may enhance HTA's market position but carries risks such as integration challenges.